Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Silence Therapeutics Promotes Tony Sedgwick To CEO - Quick Facts

Silence Therapeutics plc (SLN.L) announced the promotion of Tony Sedgwick to the role of chief executive from chief business officer, effective immediately, and the departure of Thomas Christély who has resigned as a director of the company for personal reasons but would ensure a smooth transition.

Anthony David Sedgwick, with an extensive experience from European life science companies including over 15 years at Roche, joined Silence in September 2011 to lead a new business development team. Prior to joining Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. Earlier, Tony was also CEO of two acquired companies namely Daniolabs Ltd. and Cambridge Biotechnology Ltd.

Click here to receive FREE breaking news email alerts for Silence Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After showing a notable move to the upside in early trading on Tuesday, stocks showed a substantial downturn over the course of the session. Concerns about the impact of new sanctions against Russia weighed on the markets. A day after lawmakers announced an agreement on compromise legislation to reform the Veterans Affairs Department, the Senate voted unanimously Tuesday to confirm a new head of the scandal-plagued department. Looking to increase pressure on Congress, the White House released a report on Tuesday warning of the economic costs of delaying action to address climate change.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.